Hexagon Bio
Menlo Park, US · Founded 2016 · 7 known investors
Hexagon Bio develops novel payload mechanisms for antibody-drug conjugates (ADCs) aimed at overcoming resistance to current cancer treatments and expanding ADC indications. The company focuses on targeted cytotoxic therapy for cancer, drawing on human therapeutics derived from metagenomes.
BiotechDeep TechHealthtech
Founders & leadership
Hexagon Bio was founded in 2016 by Colin James Bell Harvey, Brian T. Naughton, Maureen E. Hillenmeyer, and Maureen Hillenmeyer.
CJ
Colin James Bell HarveyCo-founder
BT
Brian T. NaughtonCo-founder
ME
Maureen E. HillenmeyerCo-founder
MH
Maureen HillenmeyerinCEO & Co-Founder
Board
AK
Alex KolichBoard director
Investors · 7
Reported raises · per SEC filings
Form D private placements$148.6M disclosed across 4 rounds · 2017–2022
▶$67.3MraisedOct 2022 · 20 investors · BiotechnologyRule 506(b)
▶$67.3MraisedOct 2022 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Juan JaenDirector
- Alex KolicichDirector
- Jakob LovenDirector
- Brian T NaughtonExecutive Officer, Director
- David GoeddelDirector
- Mridula RayDirector
- Maureen E HillenmeyerExecutive Officer, Director
- Offering amount
- $80M
- Amount sold
- $67.3M
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$61MraisedJul 2021 · 14 investors · BiotechnologyRule 506(b)
▶$61MraisedJul 2021 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Maureen HillenmeyerExecutive Officer, Director
- David GoeddelDirector
- Brian NaughtonExecutive Officer, Director
- Juan JaenDirector
- Mridula RayDirector
- Jakob LovenDirector
- Alex KolicichDirector
- Amount sold
- $61M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$12MraisedJul 2018 · 12 investors · BiotechnologyRule 506(b)
▶$12MraisedJul 2018 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brian T. NaughtonExecutive Officer, Director
- Colin James Bell HarveyExecutive Officer, Director
- Alex KolicichDirector
- Maureen E. HillenmeyerExecutive Officer, Director
- Offering amount
- $12M
- Amount sold
- $12M
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$8.3MraisedJul 2017 · 9 investors · BiotechnologyRule 506(b)
▶$8.3MraisedJul 2017 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Colin James Bell HarveyDirector
- Alex KolichDirector
- Brian T. NaughtonDirector
- Maureen E. HillenmeyerExecutive Officer, Director
- Offering amount
- $8.4M
- Amount sold
- $8.3M
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Hexagon Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Hexagon Bio do?
- Hexagon Bio develops novel payload mechanisms for antibody-drug conjugates (ADCs) aimed at overcoming resistance to current cancer treatments and expanding ADC indications. The company focuses on targeted cytotoxic therapy for cancer, drawing on human therapeutics derived from metagenomes.
- Who founded Hexagon Bio?
- Hexagon Bio was founded by Colin James Bell Harvey, Brian T. Naughton, Maureen E. Hillenmeyer, Maureen Hillenmeyer in 2016.
- Who are Hexagon Bio's investors?
- Hexagon Bio's investors include B3 Holding, Nextech Invest, SoftBank Vision Fund, The Column Group, 8VC, Casdin Capital, Two Sigma Ventures.
- How much funding has Hexagon Bio raised?
- Hexagon Bio has disclosed $148.6M raised across 4 rounds.
- Where is Hexagon Bio headquartered?
- Hexagon Bio is headquartered in Menlo Park, US.